HeliTrax FAQ Contact Us Forward to a Friend

Helixate^® FS Small Diluent Size

See how less is more: Helixate^® FS offers a small diluent size—2.5 mL. No recombinant factor VIII (rFVIII) product has a smaller diluent size. A small diluent size means less volume, which translates to fast, easy infusions for your convenience.

Helixate^® FS is now offered in a 2000 IU Vial*

Larger unit size offers greater dosing convenience for patients requiring high doses
Fewer vials shorten preparation and infusion time

Greater dosing convenience—dosing flexibility with a variety of product sizes

250 IU/2.5-mL diluent—no rFVIII product has a smaller diluent size
500 IU/2.5-mL diluent
1000 IU/2.5-mL diluent
2000 IU/5.0-mL diluent

In addition, Helixate^® FS offers:

The Mix2Vial^™ needle-free transfer device—a simpler way to reconstitute (mix) Helixate^® FS
Room temperature storage for up to 3 months
Color-coded peel-off labels to log infusions

The Helixate^® FS Difference means maximum convenience with short infusion time.

Learn more about the Mix2Vial^™ needle-free transfer device, which makes reconstituting Helixate^® FS easier than ever.

Mix2Vial is a trademark of Medimop Medical Projects Ltd.

Next: 3000 IU Dosing >>

*Requires 5.0-mL diluent

Important Safety Information

Helixate^® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate^® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate^® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Helixate® FS Small Diluent Size

Helixate^® FS Small Diluent Size